当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
RiaSTAP, Fibrinogen Concentrate (Human)
药品名称
RiaSTAP, Fibrinogen Concentrate (Human)
承诺描述
CSL Behring will conduct phase 4 study BI 3023_4003 to verify the clinical benefit by comparing the hemostatic efficacy of RiaSTAP™ to historical control.